Qiyoukang Gumokimab Application Scope

Qiyoukang® (Gumokimab, AK111) is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis. This indication is based on clinical evidence from pivotal Phase III studies conducted in China.

Gumokimab Characteristics

Ingredients: The active pharmaceutical ingredient is gumokimab.
Properties: Injection formulation (subcutaneous use).
Packaging Specification: 150 mg/1 prefilled pen per box
Storage: Store at 2–8°C, protected from light, do not freeze or shake.
Expiry Date: Refer to product packaging
Executive Standard: Not publicly disclosed.
Approval Number: Not publicly disclosed in available summary materials. (Approved by China National Medical Products Administration, NMPA)
Date of Revision: 2026 (based on approval year context; exact label revision date not publicly specified)
Manufacturer: Akeso Biopharma

Guidelines for the Use of Qiyoukang

Dosage and Administration:
- Recommended Dose: One injection per dose, totaling 17 injections per year (compared with approximately 34 injections per year for some other drugs targeting the same pathway).
- Administration: Administer subcutaneously using a prefilled single-dose injection device. The injection is designed for ease of use and may be self-administered after proper instruction from healthcare professionals.
- Missed Dose: If a dose is missed, it should be administered as soon as possible. Subsequent dosing should follow the original treatment schedule. Do not double the dose to make up for a missed injection.
Adverse Reactions:
- Common Adverse Reactions: Commonly reported reactions include upper respiratory tract infections, nasopharyngitis, and injection-site reactions.
- Serious Adverse Reactions: Serious but less common reactions may include serious infections and hypersensitivity reactions, which require medical evaluation and discontinuation if severe.
Contraindications: Qiyoukang is contraindicated in patients with known hypersensitivity to gumokimab or any component of the formulation.
Precautions:
- Patients should be evaluated for active or latent infections before initiating treatment.
- Use with caution in patients with a history of recurrent or chronic infections.
- Live vaccines should be avoided during treatment.
- Patients should be regularly monitored for signs and symptoms of infection throughout therapy.

Gumokimab Interactions

No specific drug–drug interactions have been formally established.
Caution is advised when used with other immunosuppressive agents due to potential additive effects.
Use with other biologic therapies should be carefully evaluated by healthcare professionals.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.